American Journal of Therapeutics · 2016 · 58 citations · 5 references
MedicineOncologyPharmacologyImmunopharmacologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCardiac MedicationsCardiac PharmacotherapyHeart FailureImmune Checkpoint InhibitorsImmune-related Adverse EventsAsymptomatic Left Ventricular DysfunctionCytotoxic T Lymphocyte Antigen 4Cytotoxic T-lymphocyte Antigen 4 (Ctla-4) PathwayImmune-mediated Adverse EventsImmune-mediated CardiomyopathyLeft Ventricular Diastolic DysfunctionMetastatic Melanoma TreatmentVentricular Ejection Fraction Assessment
Ipilimumab is a monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) that is approved by the US Food and Drug Administration for the treatment of unresectable or metastatic melanoma. Ipilimumab is known to cause immune-mediated adverse reactions because of the resultant increase in T-cell activity. To date, there are no published reports of ipilimumab-related heart failure, although a recently published report describes a case of transient cardiomyopathy associated with its use. We report the case of a 60-year-old man who developed left ventricular dysfunction with an asymptomatic reduction in ejection fraction from 55%-60% at baseline to 40%-45% 4 months after completing a second course of treatment with ipilimumab for metastatic melanoma. Ipilimumab was not restarted, and the patient was initiated on lisinopril and carvedilol. Repeat echocardiograms 3 and 5 months later revealed ejection fractions of 40%-45% and 55%-60%, respectively.
5
A method for estimating the probability of adverse drug reactions
C. A. Naranjo, U. Busto, Edward M. Sellers et al. · Clinical Pharmacology & Therapeutics · 1981 · 11.6K citations
Juan Carlos Plana, Maurizio Galderisi, Ana Barac et al. · Journal of the American Society of Echocardiography · 2014 · 1.8K citations · Full text